TheTechno Optimist.

Human and Organ CryopreservationAlcor Life Extension Foundation—Alcor advances kidney vitrification research with 40% success rate in preclinical models; begins antifreeze-protein gene therapy trialsHuman and Organ CryopreservationAlcor Life Extension Foundation—Alcor performs first in-house whole-body CT scan of cryopreserved patient, validating cryoprotectant distribution

Human and Organ Cryopreservation

by Alcor Life Extension FoundationUS

Preserve human and animal remains at ultra-low temperatures until future medicine can repair and revive them. Enable reversible organ preservation through vitrification and genetic engineering.

DeployStage 4 of 5

Preserving 250+ patients. Research into kidney vitrification and gene therapy ongoing.

Updated Q1 2026Checked 11 Oct0 updates this week

Milestones

Next · Kidney vitrification preclinical research ongoing
  1. Alcor founded in California1972Complete.
  2. Relocation to Scottsdale, Arizona and new cryonics facility1994Complete.
  3. 263 patients cryopreserved; 1,535 living members2026Complete.
  4. First in-house whole-body CT scan of preserved patientQ1 2026Complete.
  5. Kidney vitrification preclinical research ongoingTarget 2026Current milestone.
  6. Gene therapy trials with antifreeze proteinsTarget 2026Not yet reached.

Most important updates

Upcoming

  1. 2026Kidney vitrification preclinical research ongoing (next)
  2. 2026Gene therapy trials with antifreeze proteins
  3. 2027Large-animal organ preservation pilot studies
Primer